focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDrax Regulatory News (DRX)

Share Price Information for Drax (DRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 554.00
Bid: 553.50
Ask: 556.00
Change: 3.00 (0.54%)
Spread: 2.50 (0.452%)
Open: 552.50
High: 557.50
Low: 552.50
Prev. Close: 551.00
DRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fixed income investor calls

16 Apr 2024 10:54

RNS Number : 8178K
Drax Group PLC
16 April 2024
 

 

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO AUSTRALIA, CANADA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS RELEASE.

16 April 2024

Drax Group plc(LSE: DRX)

("the Company")

Fixed income investor calls

Drax Finco plc, a subsidiary of Drax Group plc, has mandated certain banks acting as joint bookrunners to arrange a series of fixed income investor calls on 16 and 17 April 2024.

An offering (the "Offering") of €300,000,000 five-year Senior Secured Notes (the "Notes") may follow, subject to market conditions.

If the Offering proceeds, we intend to use the expected gross proceeds (i) for general corporate purposes, which may include the repayment of indebtedness, and (ii) to pay estimated fees and expenses of the Offering, including Initial Purchasers' fees and commissions, professional fees and other associated transaction costs.

There can be no assurance that the Offering will proceed or will be completed.

Enquiries:

Drax Investor Relations: Mark Strafford

mark.strafford@drax.com

+44 (0) 7730 763 949

 

Media:

Drax External Communications: Andy Low

andrew.low@drax.com

+44 (0) 7841 068 415

 

Website: www.drax.com

Cautionary Statement

This release is being issued pursuant to Rule 135c under the U.S. Securities Act of 1933, as amended (the "Securities Act") and is for information purposes only and does not constitute a prospectus or any offer to sell or the solicitation of an offer to buy any security in the United States of America or in any other jurisdiction. The Notes have not been and will not be registered under the Securities Act, and may not be offered or sold in the United States of America absent registration or an exemption from registration under the Securities Act. If the Offering proceeds, the Notes and related guarantees will be offered in a private offering exempt from the registration requirements of the Securities Act and will accordingly be offered only to non-U.S.S persons, in offshore transactions, as defined in and in reliance on Regulation S under the Securities Act. No indebtedness incurred in connection with any other financing transactions will be registered under the Securities Act.

This communication is directed only at persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, (iii) are persons who are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons").

Any investment activity to which this communication relates will only be available to, and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This announcement is not a public offering in the Grand Duchy of Luxembourg or an offer of securities to the public under Regulation (EU) 2017/1129, and any amendments thereto.

If the Offering proceeds, the Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the "EEA") or in the United Kingdom (the "UK"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Article 4(1) of MiFID II; (ii) a customer within the meaning of the Insurance Distribution Directive), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 (as amended, the "Prospectus Regulation"). Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to retail investors in the EEA or in the UK will be prepared. Offering or selling the Notes or otherwise making them available to any retail investor in the EEA or in the UK may be unlawful under the PRIIPs Regulation. Any offer of Notes in any Member State of the EEA or in the UK will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of Notes.

If the Offering proceeds, the Manufacturer target market (MiFID II product governance) will be eligible counterparties and professional clients only (all distribution channels).

In connection with any issuance of the Notes, a stabilising manager (or person(s) acting on behalf of such stabilising manager) may over-allot Notes or effect transactions with a view to supporting the market price of the Notes at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur. Any stabilisation action may begin on or after the date on which adequate public disclosure of the terms of the offer of the Notes is made and, if begun, may be ended at any time, but it must end no later than 30 days after the date on which the issuer received the proceeds of the issue, or no later than 60 days after the date of the allotment of the Notes, whichever is earlier. Any stabilisation action or over-allotment must be conducted by the stabilising manager (or person(s) acting on behalf of the stabilising manager) in accordance with all applicable laws and rules.

Forward Looking Statements

This release includes forward-looking statements within the meaning of the securities laws of certain applicable jurisdictions. These forward-looking statements can be identified by the use of forward-looking terminology, including, but not limited to, terms such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "forecast", "guidance", "intend", "may", "outlook", "plan", "predict", "project", "should", "will" or "would" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts and include statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's future financial conditions and performance, results of operations and liquidity, strategy, plans, objectives, prospects, growth, goals and targets, future developments in the markets in which the Company participates or is seeking to participate, and anticipated regulatory changes in the industry in which the Company operates. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and are based on numerous assumptions. Given these risks and uncertainties, readers should not rely on forward looking statements as a prediction of actual results.

END

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODUNVKRSRUSARR
Date   Source Headline
28th Jun 202211:30 amRNSNotice of Change to Director Details
6th Jun 20223:01 pmRNSTotal Voting Rights
17th May 202211:34 amRNSHolding(s) in Company
12th May 20229:00 amRNSAdditional Listing
4th May 202211:03 amRNSDirector/PDMR Shareholding
3rd May 20225:03 pmRNSTotal Voting Rights
27th Apr 20223:19 pmRNSResult of AGM
27th Apr 20227:00 amRNSTrading Update
26th Apr 202212:20 pmRNSHolding(s) in Company
19th Apr 202212:00 pmRNS2022 Performance Awards - EPS Condition
8th Apr 202211:13 amRNSBlock listing Interim Review - SAYE
8th Apr 202211:11 amRNSBlock listing Interim Review - PSP
8th Apr 202211:10 amRNSBlock listing Interim Review - LTIP 2020
8th Apr 202211:08 amRNSBlock listing Interim Review - DSP
6th Apr 20223:30 pmRNSDirector/PDMR Shareholding
6th Apr 20229:00 amRNSTotal Voting Rights
30th Mar 20229:00 amRNSDirector/PDMR Shareholding
21st Mar 202210:00 amRNSDirector/PDMR Shareholding
17th Mar 20221:34 pmRNSMailing of Annual Report and Notice of AGM
16th Mar 20229:00 amRNSAdditional Listing
1st Mar 202212:39 pmRNSTotal Voting Rights
24th Feb 20227:00 amRNSAnnual Financial Report
23rd Feb 20229:00 amRNSCapacity Market Agreements
16th Feb 20222:40 pmRNSNotice of Results
7th Feb 20228:30 amRNSAdditional Listing
2nd Feb 20229:27 amRNSTotal Voting Rights
28th Jan 202212:25 pmRNSResult of audit tender
5th Jan 20228:30 amRNSAdditional Listing
4th Jan 20223:49 pmRNSTotal Voting Rights
22nd Dec 20213:05 pmRNSDirector/PDMR Shareholding
15th Dec 20217:00 amRNSInvestment in BECCS FEED Study
14th Dec 20217:00 amRNSContracts to supply 2.8Mt of biomass
1st Dec 202112:19 pmRNSTotal Voting Rights
1st Dec 20217:02 amRNSCapital Markets Day - Update
1st Dec 20217:00 amRNSTrading Update
22nd Nov 20212:25 pmRNSNotice of Capital Markets Day
5th Nov 20218:30 amRNSAdditional Listing
1st Nov 20213:07 pmRNSTotal Voting Rights
21st Oct 20211:30 pmRNSAppointment of Non-Executive Directors
6th Oct 20218:00 amRNSBlock listing Interim Review - SAYE
6th Oct 20218:00 amRNSBlock listing Interim Review - DSP
6th Oct 20218:00 amRNSBlock listing Interim Review - PSP
4th Oct 202112:11 pmRNSTotal Voting Rights
27th Sep 20218:00 amRNSAdditional Listing
23rd Sep 202111:00 amRNSINTENTION TO CONDUCT AUDIT TENDER
19th Aug 20213:34 pmRNSDirector/PDMR Shareholding
9th Aug 202111:13 amRNSLTIP 2021 – EPS Performance Condition
2nd Aug 20211:12 pmRNSTotal Voting Rights
29th Jul 20217:00 amRNSHalf-year Report
22nd Jul 20217:40 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.